Redefining the Role of Splenectomy in Scirrhous Gastric Cancer: Toward a Selective Multimodal Strategy
- 1Department of Gastric Surgery National Cancer Center Hospital Tokyo Japan
- 2Department of Gastrointestinal Surgery Yokohama City University Yokohama Japan
Abstract
Scirrhous gastric cancer, characterized by diffuse infiltration and a high propensity for peritoneal dissemination, remains one of the most aggressive subtypes of gastric cancer. Despite a relatively high incidence of splenic hilar lymph node (No. 10) metastasis, the oncologic benefit of splenectomy remains controversial, while its association with increased postoperative morbidity is well established. Recent advances in systemic therapy, including immune checkpoint inhibitors and molecular‐targeted agents, have shifted the treatment paradigm toward improved systemic disease control. In parallel, minimally invasive surgical approaches, particularly spleen‐preserving splenic hilar lymph node dissection, have emerged as feasible alternatives to conventional splenectomy. However, in scirrhous gastric cancer, disease‐specific features such as diffuse infiltration, marked fibrosis, and difficulty in intraoperative assessment continue to pose significant challenges. Furthermore, the optimal extent of lymphadenectomy, especially following neoadjuvant therapy, remains undefined. Taken together, splenectomy should no longer be regarded as a routine component of surgical management for scirrhous gastric cancer, but rather as a selective procedure tailored to individual tumor characteristics and treatment context. Future studies integrating systemic therapy, surgical safety, and oncologic adequacy are required to establish evidence‐based strategies for this challenging disease.
Related
- Reframing surgical strategy for renal cell carcinoma with inferior vena cava tumor thrombus: From classification to integrated multimodal care.
- Nanomaterials for endometriosis: a multimodal strategy integrating targeted delivery, immunomodulation, and physical ablation
- Case Report: Neurosurgery, octreotide, cabergoline, radiotherapy, pasireotide and pegvisomant – a multimodal strategy for adolescent acrogigantism
- Multimodal lifestyle intervention during neoadjuvant chemotherapy in patients with early breast cancer as a strategy to improve treatment response: Protocol of the DIANA randomized clinical trial
- #aware.hiv Europe study: protocol for a stepped-wedge cluster randomised trial of a multimodal hospital-based implementation strategy targeting HIV indicator-condition-guided testing in European hospitals
BibTeX
@article{hayashi2026redefining,
title = {{Redefining the Role of Splenectomy in Scirrhous Gastric Cancer: Toward a Selective Multimodal Strategy}},
author = {Tsutomu Hayashi and Takaki Yoshikawa},
journal = {Annals of Gastroenterological Surgery},
year = {2026},
month = jul,
doi = {10.1002/ags3.70254},
url = {https://doi.org/10.1002/ags3.70254},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Redefining the Role of Splenectomy in Scirrhous Gastric Cancer: Toward a Selective Multimodal Strategy
AU - Tsutomu Hayashi
AU - Takaki Yoshikawa
PY - 2026
DA - 2026/07/25
JO - Annals of Gastroenterological Surgery
DO - 10.1002/ags3.70254
UR - https://doi.org/10.1002/ags3.70254
AB - Scirrhous gastric cancer, characterized by diffuse infiltration and a high propensity for peritoneal dissemination, remains one of the most aggressive subtypes of gastric cancer. Despite a relatively high incidence of splenic hilar lymph node (No. 10) metastasis, the oncologic benefit of splenectomy remains controversial, while its association with increased postoperative morbidity is well established. Recent advances in systemic therapy, including immune checkpoint inhibitors and molecular‐targeted agents, have shifted the treatment paradigm toward improved systemic disease control. In parallel, minimally invasive surgical approaches, particularly spleen‐preserving splenic hilar lymph node dissection, have emerged as feasible alternatives to conventional splenectomy. However, in scirrhous gastric cancer, disease‐specific features such as diffuse infiltration, marked fibrosis, and difficulty in intraoperative assessment continue to pose significant challenges. Furthermore, the optimal extent of lymphadenectomy, especially following neoadjuvant therapy, remains undefined. Taken together, splenectomy should no longer be regarded as a routine component of surgical management for scirrhous gastric cancer, but rather as a selective procedure tailored to individual tumor characteristics and treatment context. Future studies integrating systemic therapy, surgical safety, and oncologic adequacy are required to establish evidence‐based strategies for this challenging disease.
SN - 2475-0328
ER -